{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:30:14Z","timestamp":1777440614000,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00059-022-05122-w","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T11:03:57Z","timestamp":1654686237000},"page":"324-331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cardiac amyloidosis\u2014interdisciplinary approach to diagnosis and therapy","Kardiale Amyloidose\u00a0\u2013 interdisziplin\u00e4rer Ansatz bei Diagnose und Therapie"],"prefix":"10.1007","volume":"47","author":[{"given":"A.","family":"H\u00e4nselmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Berliner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bauersachs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Bavendiek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"issue":"10038","key":"5122_CR1","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar\u00a0AD, Gillmore\u00a0JD, Hawkins\u00a0PN (2016) Systemic amyloidosis. Lancet 387(10038):2641\u20132654","journal-title":"Lancet"},{"issue":"3","key":"5122_CR2","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.cjca.2019.12.033","volume":"36","author":"SAM Cuddy","year":"2020","unstructured":"Cuddy\u00a0SAM, Falk\u00a0RH (2020) Amyloidosis as a\u00a0systemic disease in context. Can J Cardiol 36(3):396\u2013407","journal-title":"Can J Cardiol"},{"issue":"3","key":"5122_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/joim.13169","volume":"289","author":"E Muchtar","year":"2021","unstructured":"Muchtar\u00a0E, Dispenzieri\u00a0A, Magen\u00a0H et\u00a0al (2021) Systemic amyloidosis from A (AA) to T (ATTR): a\u00a0review. J\u00a0Intern Med 289(3):268\u2013292","journal-title":"J Intern Med"},{"issue":"14","key":"5122_CR4","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","volume":"135","author":"MS Maurer","year":"2017","unstructured":"Maurer\u00a0MS, Elliott\u00a0P, Comenzo\u00a0R et\u00a0al (2017) Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 135(14):1357\u20131377","journal-title":"Circulation"},{"issue":"12","key":"5122_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3949\/ccjm.84.s3.02","volume":"84","author":"JP Donnelly","year":"2017","unstructured":"Donnelly\u00a0JP, Hanna\u00a0M (2017) Cardiac amyloidosis: an update on diagnosis and treatment. Cleve Clin J Med 84(12):12\u201326","journal-title":"Cleve Clin J Med"},{"issue":"4","key":"5122_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","volume":"110","author":"A Yilmaz","year":"2021","unstructured":"Yilmaz\u00a0A, Bauersachs\u00a0J, Bengel\u00a0F et\u00a0al (2021) Diagnosis and treatment of cardiac amyloidosis: position statement of the German cardiac society (DGK). Clin Res Cardiol 110(4):479\u2013506","journal-title":"Clin Res Cardiol"},{"issue":"16","key":"5122_CR7","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia\u00a0P, Rapezzi\u00a0C, Adler\u00a0Y et al (2021) Diagnosis and treatment of cardiac amyloidosis: a\u00a0position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart\u00a0J 42(16):1554\u20131568","journal-title":"Eur Heart J"},{"issue":"8","key":"5122_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","volume":"47","author":"PN Hawkins","year":"2015","unstructured":"Hawkins\u00a0PN, Ando\u00a0Y, Dispenzeri\u00a0A et\u00a0al (2015) Evolving landscape in the management of transthyretin amyloidosis. Ann Med 47(8):625\u2013638","journal-title":"Ann Med"},{"issue":"1","key":"5122_CR9","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1080\/07853890.2021.1988696","volume":"53","author":"V Skrahina","year":"2021","unstructured":"Skrahina\u00a0V, Grittner\u00a0U, Beetz\u00a0C et al (2021) Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology. Ann Med 53(1):1787\u20131796","journal-title":"Ann Med"},{"key":"5122_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04889-2","author":"F Manganelli","year":"2020","unstructured":"Manganelli\u00a0F, Fabrizi\u00a0GM, Luigetti\u00a0M et\u00a0al (2020) Hereditary transthyretin amyloidosis overview. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-020-04889-2","journal-title":"Neurol Sci"},{"issue":"16","key":"5122_CR11","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMc1917321","volume":"382","author":"S Ravichandran","year":"2020","unstructured":"Ravichandran\u00a0S, Lachmann\u00a0HJ, Wechalekar\u00a0AD (2020) Epidemiologic and survival trends in amyloidosis, 1987\u20132019. N\u00a0Engl J Med 382(16):1567\u20131568","journal-title":"N Engl J Med"},{"key":"5122_CR12","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/blood-2021-152713","volume":"138","author":"U Hegenbart","year":"2021","unstructured":"Hegenbart\u00a0U, Fuhr\u00a0N, Huber\u00a0L et al (2021) Two-year evaluation of the German clinical amyloidosis registry. Blood 138:3780","journal-title":"Blood"},{"issue":"38","key":"5122_CR13","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Castano","year":"2017","unstructured":"Castano\u00a0A, Narotsky\u00a0DL, Hamid\u00a0N et\u00a0al (2017) Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart\u00a0J 38(38):2879\u20132887","journal-title":"Eur Heart J"},{"issue":"38","key":"5122_CR14","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonzalez-Lopez","year":"2015","unstructured":"Gonzalez-Lopez\u00a0E, Gallego-Delgado\u00a0M, Guzzo-Merello\u00a0G et al (2015) Wild-type transthyretin amyloidosis as a\u00a0cause of heart failure with preserved ejection fraction. Eur Heart\u00a0J 36(38):2585\u20132594","journal-title":"Eur Heart J"},{"issue":"10","key":"5122_CR15","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","volume":"2","author":"TP Quock","year":"2018","unstructured":"Quock\u00a0TP, Yan\u00a0T, Chang\u00a0E et al (2018) Epidemiology of AL amyloidosis: a\u00a0real-world study using US claims data. Blood Adv 2(10):1046\u20131053","journal-title":"Blood Adv"},{"issue":"8","key":"5122_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","volume":"7","author":"RM Witteles","year":"2019","unstructured":"Witteles\u00a0RM, Bokhari\u00a0S, Damy\u00a0T et\u00a0al (2019) Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail 7(8):709\u2013716","journal-title":"JACC Heart Fail"},{"issue":"9","key":"5122_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar\u00a0S, Dispenzieri\u00a0A, Lacy\u00a0MQ et\u00a0al (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J\u00a0Clin Oncol 30(9):989\u2013995","journal-title":"J Clin Oncol"},{"issue":"30","key":"5122_CR18","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore\u00a0JD, Damy\u00a0T, Fontana\u00a0M et\u00a0al (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart\u00a0J 39(30):2799\u20132806","journal-title":"Eur Heart J"},{"issue":"8","key":"5122_CR19","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","volume":"55","author":"JA Katzmann","year":"2009","unstructured":"Katzmann\u00a0JA, Kyle\u00a0RA, Benson\u00a0J et\u00a0al (2009) Screening panels for detection of monoclonal gammopathies. Clin Chem 55(8):1517\u20131522","journal-title":"Clin Chem"},{"issue":"9","key":"5122_CR20","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","volume":"48","author":"JA Katzmann","year":"2002","unstructured":"Katzmann\u00a0JA, Clark\u00a0RJ, Abraham\u00a0RS et\u00a0al (2002) Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48(9):1437\u20131444","journal-title":"Clin Chem"},{"issue":"19","key":"5122_CR21","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","volume":"98","author":"D Phelan","year":"2012","unstructured":"Phelan\u00a0D, Collier\u00a0P, Thavendiranathan\u00a0P et al (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98(19):1442\u20131448","journal-title":"Heart"},{"issue":"4","key":"5122_CR22","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","volume":"13","author":"M Boldrini","year":"2020","unstructured":"Boldrini\u00a0M, Cappelli\u00a0F, Chacko\u00a0L et\u00a0al (2020) Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 13(4):909\u2013920","journal-title":"JACC Cardiovasc Imaging"},{"issue":"10","key":"5122_CR23","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jacc.2007.10.049","volume":"51","author":"H Vogelsberg","year":"2008","unstructured":"Vogelsberg\u00a0H, Mahrholdt\u00a0H, Deluigi\u00a0CC et\u00a0al (2008) Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J\u00a0Am Coll Cardiol 51(10):1022\u20131030","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"5122_CR24","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","volume":"6","author":"TD Karamitsos","year":"2013","unstructured":"Karamitsos\u00a0TD, Piechnik\u00a0SK, Banypersad\u00a0SM et\u00a0al (2013) Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 6(4):488\u2013497","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"5122_CR25","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.jcmg.2020.03.010","volume":"13","author":"JA Pan","year":"2020","unstructured":"Pan\u00a0JA, Kerwin\u00a0MJ, Salerno\u00a0M (2020) Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis. JACC Cardiovasc Imaging 13(6):1299\u20131310","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"5122_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcmg.2009.09.023","volume":"3","author":"IS Syed","year":"2010","unstructured":"Syed\u00a0IS, Glockner\u00a0JF, Feng\u00a0D et\u00a0al (2010) Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 3(2):155\u2013164","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"5122_CR27","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","volume":"26","author":"S Dorbala","year":"2019","unstructured":"Dorbala\u00a0S, Ando\u00a0Y, Bokhari\u00a0S et al (2019) ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2\u2011evidence base and standardized methods of imaging. J\u00a0Nucl Cardiol 26(6):2065\u20132123","journal-title":"J Nucl Cardiol"},{"issue":"6","key":"5122_CR28","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini\u00a0E, Guidalotti\u00a0PL, Salvi\u00a0F et al (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc\u20113,3\u2011diphosphono\u20111,2\u2011propanodicarboxylic acid scintigraphy. J\u00a0Am Coll Cardiol 46(6):1076\u20131084","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"5122_CR29","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore\u00a0JD, Maurer\u00a0MS, Falk\u00a0RH et\u00a0al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133(24):2404\u20132412","journal-title":"Circulation"},{"issue":"13","key":"5122_CR30","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1161\/CIRCULATIONAHA.121.055517","volume":"144","author":"MS Maurer","year":"2021","unstructured":"Maurer\u00a0MS, Ruberg\u00a0FL (2021) Cardiac scintigraphy and screening for transthyretin cardiac amyloidosis: caveat emptor. Circulation 144(13):1005\u20131007","journal-title":"Circulation"},{"issue":"5","key":"5122_CR31","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.ahj.2003.09.020","volume":"147","author":"H Ardehali","year":"2004","unstructured":"Ardehali\u00a0H, Qasim\u00a0A, Cappola\u00a0T et\u00a0al (2004) Endomyocardial biopsy plays a\u00a0role in diagnosing patients with unexplained cardiomyopathy. Am Heart\u00a0J 147(5):919\u2013923","journal-title":"Am Heart J"},{"key":"5122_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.humpath.2017.11.001","volume":"72","author":"Y Garcia","year":"2018","unstructured":"Garcia\u00a0Y, Collins\u00a0AB, Stone\u00a0JR (2018) Abdominal fat pad excisional biopsy for the diagnosis and typing of systemic amyloidosis. Hum Pathol 72:71\u201379","journal-title":"Hum Pathol"},{"issue":"4","key":"5122_CR33","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","volume":"3","author":"JM Griffin","year":"2021","unstructured":"Griffin\u00a0JM, Rosenthal\u00a0JL, Grodin\u00a0JL et al (2021) ATTR amyloidosis: current and emerging management strategies: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 3(4):488\u2013505","journal-title":"JACC CardioOncol"},{"issue":"4","key":"5122_CR34","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","volume":"3","author":"G Bianchi","year":"2021","unstructured":"Bianchi\u00a0G, Zhang\u00a0Y, Comenzo\u00a0RL (2021) AL amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 3(4):467\u2013487","journal-title":"JACC CardioOncol"},{"issue":"13","key":"5122_CR35","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/0002-9149(85)90995-6","volume":"55","author":"MA Gertz","year":"1985","unstructured":"Gertz\u00a0MA, Falk\u00a0RH, Skinner\u00a0M et al (1985) Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol 55(13):1645","journal-title":"Am J Cardiol"},{"key":"5122_CR36","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.amjcard.2020.07.034","volume":"133","author":"JP Donnelly","year":"2020","unstructured":"Donnelly\u00a0JP, Sperry\u00a0BW, Gabrovsek\u00a0A et\u00a0al (2020) Digoxin use in cardiac amyloidosis. Am J Cardiol 133:134\u2013138","journal-title":"Am J Cardiol"},{"issue":"11","key":"5122_CR37","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer\u00a0MS, Schwartz\u00a0JH, Gundapaneni\u00a0B et\u00a0al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N\u00a0Engl J Med 379(11):1007\u20131016","journal-title":"N Engl J Med"},{"issue":"8","key":"5122_CR38","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho\u00a0T, Maia\u00a0LF, Martins da Silva\u00a0A et\u00a0al (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a\u00a0randomized, controlled trial. Neurology 79(8):785\u2013792","journal-title":"Neurology"},{"issue":"11","key":"5122_CR39","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","volume":"260","author":"T Coelho","year":"2013","unstructured":"Coelho\u00a0T, Maia\u00a0LF, Martins da Silva\u00a0A et al (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J\u00a0Neurol 260(11):2802\u20132814","journal-title":"J Neurol"},{"issue":"3","key":"5122_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","volume":"74","author":"DP Judge","year":"2019","unstructured":"Judge\u00a0DP, Heitner\u00a0SB, Falk\u00a0RH et\u00a0al (2019) Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J\u00a0Am Coll Cardiol 74(3):285\u2013295","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"5122_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson\u00a0MD, Waddington-Cruz\u00a0M, Berk\u00a0JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N\u00a0Engl J Med 379(1):22\u201331","journal-title":"N Engl J Med"},{"issue":"1","key":"5122_CR42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","volume":"27","author":"NR Dasgupta","year":"2020","unstructured":"Dasgupta\u00a0NR, Rissing\u00a0SM, Smith\u00a0J et\u00a0al (2020) Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid 27(1):52\u201358","journal-title":"Amyloid"},{"issue":"1","key":"5122_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams\u00a0D, Gonzalez-Duarte\u00a0A, O\u2019Riordan\u00a0WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N\u00a0Engl J Med 379(1):11\u201321","journal-title":"N Engl J Med"},{"issue":"4","key":"5122_CR44","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon\u00a0SD, Adams\u00a0D, Kristen\u00a0A et al (2019) Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 139(4):431\u2013443","journal-title":"Circulation"},{"issue":"1","key":"5122_CR45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","volume":"14","author":"M Fontana","year":"2021","unstructured":"Fontana\u00a0M, Martinez-Naharro\u00a0A, Chacko\u00a0L et al (2021) Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging 14(1):189\u2013199","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"5122_CR46","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis\u00a0E, Palladini\u00a0G, Minnema\u00a0MC et al (2021) Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N\u00a0Engl J Med 385(1):46\u201358","journal-title":"N Engl J Med"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05122-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-022-05122-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05122-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T09:05:28Z","timestamp":1659690328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-022-05122-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["5122"],"URL":"https:\/\/doi.org\/10.1007\/s00059-022-05122-w","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,8]]},"assertion":[{"value":"27 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.\u00a0H\u00e4nselmann received honoraria and\/or travel support from Novartis, Bayer, Boehringer Ingelheim, Abiomed, Alnylam, Pfizer.D.\u00a0Berliner received honoraria and\/or travel support from Abbott, Bayer, Biotronik, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Orion Pharma, and Pfizer, and research support from CVRx, Novartis, and Zoll.J.\u00a0Bauersachs received honoraria for lectures\/consulting from Novartis, Vifor, Bayer, Pfizer, Boehringer Ingelheim, AstraZeneca, Cardior, CVRx, BMS, Amgen, Corvia, not related to this article; and research support for the department from Zoll, CVRx, Abiomed, not related to this article.U.\u00a0Bavendiek received honoraria and\/or travel support from Astra Zeneca, Alnylam, Amgen, Bayer, Pfizer, and research support from Alnylam.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}